Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN)
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
In this study, the investigators designed a treatment regimen including the most active
agents in pancreatic cancer which are gemcitabine and fluorouracil to be tested as a first
line treatment. This regimen is expected to be less toxic than FOLFIRINOX and aiming at
better outcomes.